Visualize more biomarkers and extract more insights Moving from single marker IHC to multiplex IF
Scott Lawrence - Associate Scientist, Cancer Genetics Research Group at Leidos
Katir Patel - Associate Director, Biomarker Applications at Ultivue
There is an increasing need to evaluate and understand unique phenotypes and mechanisms of action within the tissue tumor microenvironment. Conventional assays such as chromogenic immunohistochemistry (IHC) allow researchers to rapidly evaluate biomarker expression and staining patterns. Chromogenic IHC is often limited to single-marker same-slide staining, thus the need to stain multiple serial sections. This leads to a lack of proper cell phenotyping and spatial relationship mapping.
Ultivue’s InSituPlex® technology enables pathology scientists to perform an in depth investigation of multiple markers (up to 8) on a single tissue section allowing for multi-marker cell phenotyping at a high throughput rate compared to other multiplex immunofluorescence (IF) techniques.
In this webinar, Scott Lawrence of Cancer Genetics Research Laboratory will share how his lab, using InSituPlex technology, is transitioning single-marker IHC assays to comprehensive multiplex immunofluorescence assays in order to gain more insights per sample.
- Introduction to the InSituPlex® technology
- Understanding of the UltiMapper™ kit portfolio and assay workflow
- Learn the benefits and setbacks of using chromogenic IHC and multiplex IF